Nothing Special   »   [go: up one dir, main page]

MX2016000095A - Transtornos neurodegenerativos. - Google Patents

Transtornos neurodegenerativos.

Info

Publication number
MX2016000095A
MX2016000095A MX2016000095A MX2016000095A MX2016000095A MX 2016000095 A MX2016000095 A MX 2016000095A MX 2016000095 A MX2016000095 A MX 2016000095A MX 2016000095 A MX2016000095 A MX 2016000095A MX 2016000095 A MX2016000095 A MX 2016000095A
Authority
MX
Mexico
Prior art keywords
neurodegenerative disorders
acetylcholinesterase
ach
truncation
terminus
Prior art date
Application number
MX2016000095A
Other languages
English (en)
Inventor
Greenfield Susan
Original Assignee
Neuro-Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro-Bio Ltd filed Critical Neuro-Bio Ltd
Publication of MX2016000095A publication Critical patent/MX2016000095A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Un polipéptido cíclico, derivado o uno de sus análogos, que comprende una secuencia de aminoácidos derivada del extremo C-terminal de acetilcolinesterasa (AChE), o uno de sus truncamientos.
MX2016000095A 2013-07-09 2014-07-04 Transtornos neurodegenerativos. MX2016000095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1312279.1A GB2516045A (en) 2013-07-09 2013-07-09 Neurodegenerative disorders
PCT/GB2014/052041 WO2015004430A1 (en) 2013-07-09 2014-07-04 Neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2016000095A true MX2016000095A (es) 2016-08-12

Family

ID=49033534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000095A MX2016000095A (es) 2013-07-09 2014-07-04 Transtornos neurodegenerativos.

Country Status (12)

Country Link
US (2) US10053677B2 (es)
EP (1) EP3019591B1 (es)
JP (1) JP6647199B2 (es)
KR (1) KR102436886B1 (es)
CN (1) CN105531383B (es)
AU (2) AU2014289001C1 (es)
BR (1) BR112016000565B1 (es)
CA (1) CA2917389C (es)
ES (1) ES2650543T3 (es)
GB (1) GB2516045A (es)
MX (1) MX2016000095A (es)
WO (1) WO2015004430A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539161A (en) 2014-11-26 2016-12-14 Neuro-Bio Ltd Neurodegenerative disorders
GB2538947A (en) * 2014-12-19 2016-12-07 Neuro-Bio Ltd Cancer
GB201613999D0 (en) * 2016-08-16 2016-09-28 Neuro-Bio Ltd Neurodegenerative disorders
GB201705044D0 (en) * 2017-03-29 2017-05-10 Neuro-Bio Ltd Biomarker
GB2587211A (en) * 2019-09-18 2021-03-24 Neuro Bio Ltd Animal model
GB202004803D0 (en) * 2020-04-01 2020-05-13 Neuro Bio Ltd Skin
GB202004804D0 (en) * 2020-04-01 2020-05-13 Neuro Bio Ltd Skin
GB202014080D0 (en) * 2020-09-08 2020-10-21 Neuro Bio Ltd Down's syndrome
BR112023012422A2 (pt) 2021-01-24 2023-12-12 Michael David Forrest Inibidores da atp sintase - usos cosmético e terapêutico
KR20230165640A (ko) 2022-05-27 2023-12-05 가천대학교 산학협력단 혈액 엑소좀 단백질 양 및 아세틸콜린 에스터레이즈 활성도에 기초한 파킨슨 병 진단 방법
WO2024052650A1 (en) 2022-09-08 2024-03-14 Neuro-Bio Ltd Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
GB202306078D0 (en) 2023-04-25 2023-06-07 Neuro Bio Ltd Neurodegenerative disorders
GB202306126D0 (en) * 2023-04-26 2023-06-07 Neuro Bio Ltd Treatment of rapamycin-sensitive conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777073A (en) * 1994-12-12 1998-07-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
IL131707A0 (en) * 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
GB9930825D0 (en) * 1999-12-30 2000-02-16 Synaptica Limited Animal models for neurodegenerative disease
US20030092613A1 (en) * 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
CA2825519A1 (en) * 2011-02-03 2012-09-08 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr

Also Published As

Publication number Publication date
JP2016525095A (ja) 2016-08-22
US11091747B2 (en) 2021-08-17
GB201312279D0 (en) 2013-08-21
KR102436886B1 (ko) 2022-08-25
BR112016000565A2 (pt) 2019-03-19
AU2018260893B2 (en) 2020-05-07
WO2015004430A9 (en) 2015-03-12
CN105531383A (zh) 2016-04-27
AU2014289001B2 (en) 2018-08-09
JP6647199B2 (ja) 2020-02-14
AU2018260893A1 (en) 2018-11-29
BR112016000565B1 (pt) 2023-11-07
US20160369250A1 (en) 2016-12-22
CN105531383B (zh) 2020-04-21
CA2917389C (en) 2023-09-26
EP3019591B1 (en) 2017-08-30
CA2917389A1 (en) 2015-01-15
US10053677B2 (en) 2018-08-21
AU2014289001A1 (en) 2016-02-25
GB2516045A (en) 2015-01-14
AU2014289001C1 (en) 2019-04-04
NZ716647A (en) 2022-03-25
US20190100735A1 (en) 2019-04-04
KR20160078950A (ko) 2016-07-05
EP3019591A1 (en) 2016-05-18
US20210388331A1 (en) 2021-12-16
ES2650543T3 (es) 2018-01-19
WO2015004430A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
MX2016000095A (es) Transtornos neurodegenerativos.
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
PH12016501151A1 (en) Nrf2 regulators
CA2921232A1 (en) Adeno-associated virus factor viii vectors
MX2016011641A (es) Procedimiento de preparacion de proteinas plasmaticas humanas.
MX2020004073A (es) Procesos de siembra en serie y usos de los mismos.
PH12015502412B1 (en) Engineered phenylalanine ammonia lyase polypeptides
MX2022013454A (es) Moduladores de la actividad del complemento.
MX2018001793A (es) Compuestos para dispositivos opticamente activos.
IL251571A0 (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
HK1254601A1 (zh) 新型肽
EP3645031A4 (en) PEPTIDIC ANALOGUES
EP3377471A4 (en) SYNTHESIS OF FRAGMENTS OF CYCLIC PEPTIDES
MX366636B (es) Nuevo derivado de un análogo de insulina.
WO2014145897A3 (en) Immunotherapy system and method thereof
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
SA517380723B1 (ar) rHu-GCSF طريقة لتنقية
EP3733686A4 (en) NEW PEPTIDE
EP3380115B8 (en) Peptides from piwil1
GB201700557D0 (en) Novel peptides
MX2017006692A (es) Trastornos neurodegenerativos.
MX358078B (es) Acido (s)-3'-metil-abscisico y esteres del mismo.
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
EP3441401A4 (en) PEPTIDE PENETRATING IN CELLS
MX2016016397A (es) Proceso para preparar 3-cloro-2-vinilfenol.

Legal Events

Date Code Title Description
FG Grant or registration